Jiangsu wuzhong(SH:600200) Shang Hai Zheng Quan Bao·2025-09-25 19:18Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is facing significant risks of being delisted due to suspected violations of information disclosure regulations, as confirmed by the China Securities Regulatory Commission (CSRC) [2][4][5] Group 1: Investigation and Regulatory Actions - The company has been under investigation by the CSRC since February 26, 2025, for suspected information disclosure violations [4] - On July 13, 2025, the CSRC issued a notice indicating that the company inflated its revenue, costs, and profits from 2020 to 2023, which could lead to mandatory delisting [5][6] - The company has been placed under a warning for major illegal delisting risks since July 14, 2025, following the CSRC's findings [2][5] Group 2: Financial Performance and Risks - The company reported a net loss of 44.42 million yuan for the first half of 2025, a decline of 281.63% compared to the same period last year [3][7] - There are multiple delisting risks, including unresolved large fund occupation by the controlling shareholder and the freezing of all shares held by the controlling shareholder [3][6] - The company has been warned about financial delisting risks due to an inability to express an opinion on its 2024 financial report [6] Group 3: Future Implications - If the formal penalty decision confirms the violations, the company will apply for a trading suspension and disclose relevant information promptly [2][8] - The Shanghai Stock Exchange will issue a notice regarding the potential termination of the company's stock listing within five trading days after the suspension [2][8]